{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:54:19Z","timestamp":1773712459375,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunoglobulin A nephropathy (IgAN) is a common autoimmune glomerulonephritis that can result in end-stage renal disease (ESRD). Whether immunosuppressants are superior or equivalent to supportive care is still controversial. A network meta-analysis was conducted to compare the efficacy and safety of immunosuppressive treatment for IgAN. Medline, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and EMBASE were searched on December 30, 2018. We used a random-effects model with a Bayesian approach to appraise both renal outcomes and serious adverse effects. Relative risks (RRs) with 95% confidence intervals (CIs) were calculated to present the relative effects. The ranking probabilities were calculated by the surface under the cumulative ranking curve (SUCRA). In total, 24 RCTs comprising 6 interventions were analyzed. Steroids significantly delayed the progression of renal deterioration with acceptable serious adverse effects, compared with supportive care (RR\u2009=\u20090.28, 95% CI\u2009=\u20090.13\u20130.51, SUCRA\u2009=\u200948.7%). AZA combined with steroids might be an alternative immunosuppressive therapy. Tacrolimus might decrease the proteinuria level (RR\u2009=\u20093.1, 95% CI\u2009=\u20091.2\u20139.4, SUCRA\u2009=\u200966.5%) but cannot improve renal function, and the side effects of tacrolimus should not be neglected. MMF and CYC showed no superiority in the treatment of IgAN. In summary, steroids might be recommended as the first-line immunosuppressive therapy for IgAN.<\/jats:p>","DOI":"10.1038\/s41598-020-63170-w","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T10:03:12Z","timestamp":1586340192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"Jiaxing","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingqiu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengyue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padamata","family":"Tarun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"63170_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt, R. J. & Julian, B. A. IgA nephropathy. The New England journal of medicine 368, 2402\u20132414, https:\/\/doi.org\/10.1056\/NEJMra1206793 (2013).","journal-title":"The New England journal of medicine"},{"key":"63170_CR2","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1681\/ASN.V11101957","volume":"11","author":"J Berger","year":"2000","unstructured":"Berger, J., Hinglas, N. & Striker, L. Intercapillary deposits of IgA-IgC. Journal of the American Society of Nephrology: JASN 11, 1957\u20131959 (2000).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"63170_CR3","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1038\/sj.ki.5000434","volume":"69","author":"GB Appel","year":"2006","unstructured":"Appel, G. B. & Waldman, M. The IgA nephropathy treatment dilemma. Kidney international 69, 1939\u20131944, https:\/\/doi.org\/10.1038\/sj.ki.5000434 (2006).","journal-title":"Kidney international"},{"key":"63170_CR4","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/jci74475","volume":"124","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk, K. & Novak, J. The genetics and immunobiology of IgA nephropathy. The Journal of clinical investigation 124, 2325\u20132332, https:\/\/doi.org\/10.1172\/jci74475 (2014).","journal-title":"The Journal of clinical investigation"},{"key":"63170_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3892\/etm.2015.2860","volume":"11","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis. Experimental and therapeutic medicine 11, 49\u201356, https:\/\/doi.org\/10.3892\/etm.2015.2860 (2016).","journal-title":"Experimental and therapeutic medicine"},{"key":"63170_CR6","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J. P. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.) 343, d5928, https:\/\/doi.org\/10.1136\/bmj.d5928 (2011).","journal-title":"BMJ (Clinical research ed.)"},{"key":"63170_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti, G., Ades, A. E. & Ioannidis, J. P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of clinical epidemiology 64, 163\u2013171, https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016 (2011).","journal-title":"Journal of clinical epidemiology"},{"key":"63170_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1681\/asn.2017060713","volume":"29","author":"T Rauen","year":"2018","unstructured":"Rauen, T. et al. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. Journal of the American Society of Nephrology: JASN 29, 317\u2013325, https:\/\/doi.org\/10.1681\/asn.2017060713 (2018).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"63170_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv, J. et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. Jama 318, 432\u2013442, https:\/\/doi.org\/10.1001\/jama.2017.9362 (2017).","journal-title":"Jama"},{"key":"63170_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/s0140-6736(17)30550-0","volume":"389","author":"BC Fellstrom","year":"2017","unstructured":"Fellstrom, B. C. et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet (London, England) 389, 2117\u20132127, https:\/\/doi.org\/10.1016\/s0140-6736(17)30550-0 (2017).","journal-title":"Lancet (London, England)"},{"key":"63170_CR11","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno, C., Torres, D. D., Rossini, M., Pesce, F. & Schena, F. P. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 24, 3694\u20133701, https:\/\/doi.org\/10.1093\/ndt\/gfp356 (2009).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"63170_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv, J. et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. American journal of kidney diseases: the official journal of the National Kidney Foundation 53, 26\u201332, https:\/\/doi.org\/10.1053\/j.ajkd.2008.07.029 (2009).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"63170_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2215\/cjn.01020905","volume":"1","author":"RJ Hogg","year":"2006","unstructured":"Hogg, R. J. et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clinical journal of the American Society of Nephrology: CJASN 1, 467\u2013474, https:\/\/doi.org\/10.2215\/cjn.01020905 (2006).","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"63170_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi, C. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. Journal of the American Society of Nephrology: JASN 15, 157\u2013163 (2004).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"63170_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","volume":"41","author":"R Katafuchi","year":"2003","unstructured":"Katafuchi, R. et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. American journal of kidney diseases: the official journal of the National Kidney Foundation 41, 972\u2013983 (2003).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"63170_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0272-6386(00)70326-X","volume":"35","author":"T Shoji","year":"2000","unstructured":"Shoji, T. et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy. American journal of kidney diseases: the official journal of the National Kidney Foundation 35, 194\u2013201 (2000).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"63170_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000422413","volume":"104","author":"BA Julian","year":"1993","unstructured":"Julian, B. A. & Barker, C. Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Contributions to nephrology 104, 198\u2013206 (1993).","journal-title":"Contributions to nephrology"},{"key":"63170_CR18","first-page":"174","volume":"26","author":"KN Lai","year":"1986","unstructured":"Lai, K. N., Lai, F. M., Ho, C. P. & Chan, K. W. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clinical nephrology 26, 174\u2013180 (1986).","journal-title":"Clinical nephrology"},{"key":"63170_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"RJ Hogg","year":"2015","unstructured":"Hogg, R. J. et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. American journal of kidney diseases: the official journal of the National Kidney Foundation 66, 783\u2013791, https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.013 (2015).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"63170_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ki.2009.499","volume":"77","author":"SC Tang","year":"2010","unstructured":"Tang, S. C. et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney international 77, 543\u2013549, https:\/\/doi.org\/10.1038\/ki.2009.499 (2010).","journal-title":"Kidney international"},{"key":"63170_CR21","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch, G. et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 20, 2139\u20132145, https:\/\/doi.org\/10.1093\/ndt\/gfh974 (2005).","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association"},{"key":"63170_CR22","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes, B. D. et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney international 65, 1842\u20131849, https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00588.x (2004).","journal-title":"Kidney international"},{"key":"63170_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou, J. H. et al. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. American journal of kidney diseases: the official journal of the National Kidney Foundation 69, 788\u2013795, https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.027 (2017).","journal-title":"American journal of kidney diseases: the official journal of the National Kidney Foundation"},{"key":"63170_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5414\/cp201887","volume":"52","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. Treatment of severe IgA nephropathy: mycophenolate mofetil\/prednisone compared to cyclophosphamide\/prednisone. International journal of clinical pharmacology and therapeutics 52, 95\u2013102, https:\/\/doi.org\/10.5414\/cp201887 (2014).","journal-title":"International journal of clinical pharmacology and therapeutics"},{"key":"63170_CR25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie, F. W. & Roberts, I. S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. Journal of the American Society of Nephrology: JASN 13, 142\u2013148 (2002).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"63170_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2215\/cjn.08630910","volume":"6","author":"K Kamei","year":"2011","unstructured":"Kamei, K. et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clinical journal of the American Society of Nephrology: CJASN 6, 1301\u20131307, https:\/\/doi.org\/10.2215\/cjn.08630910 (2011).","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"63170_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1014424723466","volume":"33","author":"O Harmankaya","year":"2002","unstructured":"Harmankaya, O., Ozturk, Y., Basturk, T., Obek, A. & Kilicarslan, I. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. International urology and nephrology 33, 167\u2013171 (2002).","journal-title":"International urology and nephrology"},{"key":"63170_CR28","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/asn.2010010117","volume":"21","author":"C Pozzi","year":"2010","unstructured":"Pozzi, C. et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. Journal of the American Society of Nephrology: JASN 21, 1783\u20131790, https:\/\/doi.org\/10.1681\/asn.2010010117 (2010).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"63170_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2215\/cjn.01120905","volume":"1","author":"N Yoshikawa","year":"2006","unstructured":"Yoshikawa, N. et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clinical journal of the American Society of Nephrology: CJASN 1, 511\u2013517, https:\/\/doi.org\/10.2215\/cjn.01120905 (2006).","journal-title":"Clinical journal of the American Society of Nephrology: CJASN"},{"key":"63170_CR30","doi-asserted-by":"publisher","first-page":"e0188375","DOI":"10.1371\/journal.pone.0188375","volume":"12","author":"MY Yu","year":"2017","unstructured":"Yu, M. Y., Kim, Y. C., Koo, H. S. & Chin, H. J. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study. PloS one 12, e0188375, https:\/\/doi.org\/10.1371\/journal.pone.0188375 (2017).","journal-title":"PloS one"},{"key":"63170_CR31","doi-asserted-by":"publisher","first-page":"e71545","DOI":"10.1371\/journal.pone.0071545","volume":"8","author":"YC Kim","year":"2013","unstructured":"Kim, Y. C., Chin, H. J., Koo, H. S. & Kim, S. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PloS one 8, e71545, https:\/\/doi.org\/10.1371\/journal.pone.0071545 (2013).","journal-title":"PloS one"},{"key":"63170_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","volume":"53","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial. Internal medicine (Tokyo, Japan) 53, 675\u2013681 (2014).","journal-title":"Internal medicine (Tokyo, Japan)"},{"key":"63170_CR33","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen, T. et al. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. The New England journal of medicine 373, 2225\u20132236, https:\/\/doi.org\/10.1056\/NEJMoa1415463 (2015).","journal-title":"The New England journal of medicine"},{"key":"63170_CR34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1159\/000492592","volume":"43","author":"L Tan","year":"2018","unstructured":"Tan, L., Tang, Y., Peng, W., Mathew, B. S. & Qin, W. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy. Kidney & blood pressure research 43, 1333\u20131343, https:\/\/doi.org\/10.1159\/000492592 (2018).","journal-title":"Kidney & blood pressure research"},{"key":"63170_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","volume":"28","author":"XH Shen","year":"2015","unstructured":"Shen, X. H. et al. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. Journal of nephrology 28, 441\u2013449, https:\/\/doi.org\/10.1007\/s40620-014-0165-x (2015).","journal-title":"Journal of nephrology"},{"key":"63170_CR36","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1177\/0300060518776566","volume":"46","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y., Luo, J., Hu, B. & Ma, T. Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis. The Journal of international medical research 46, 3236\u20133250, https:\/\/doi.org\/10.1177\/0300060518776566 (2018).","journal-title":"The Journal of international medical research"},{"key":"63170_CR37","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1046\/j.1523-1755.2000.00032.x","volume":"57","author":"SI Hsu","year":"2000","unstructured":"Hsu, S. I., Ramirez, S. B., Winn, M. P., Bonventre, J. V. & Owen, W. F. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney international 57, 1818\u20131835, https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00032.x (2000).","journal-title":"Kidney international"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63170-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63170-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:06:07Z","timestamp":1670317567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63170-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63170"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63170-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6062"}}